The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The transcriptional regulator c-JUN is a key mediator of the metastatic potential and drug resistance in melanoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, c-JUN induces an EMT-like phenotype switch that may be responsible for the adaptive resistance to BRAF-MEK-ERK pathway inhibition in BRAFV600E melanoma cells [56].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [56]
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“Functional category enrichment analysis using the NCBI Database for Annotation, Visualization and IntegratedDiscovery (DAVID) functional annotation toolwas used to identify GO terms (58) for the significant differentially expressed gene set.”
MethodSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“These morphological and expression pattern alterations were consistent with previous descriptions of EMT programs in epithelial cancers (28) and of the phenotypic switch in melanoma (33).”
BackgroundResultImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citation
Cited by
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
“The JNK signaling pathway mediates a wide range of cellular processes, including cell proliferation, survival, and migration [4,18,19], as well as cell apoptosis, senescence, and stress responses [20,21] (Figure 2).”
BackgroundThe CRUK IMAXT Grand Challenge Team, O’Flanagan, C. H., Campbell, K. R., Zhang, A. W., Kabeer, F., Lim, J. L. P., Biele, J., Eirew, P., Lai, D., McPherson, A., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1830-0 · Cited by 269
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
“Exposure of BRAF-mutant melanoma cells to MAPK inhibitors initially induces up-regulation of JNK/c-Jun signaling, a known regulator of EMT-related genes and of cell adhesion and ECM molecules (Liu et al, 2015; Ramsdale et al, 2015).”
Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., Garcia-Diaz, A., Homet Moreno, B., Kim, J., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 228
“Extended exposure (>2 wk) can yield an invasive mesenchymal-like state with both MART-1 and NGFR loss (3).”
BackgroundResultvan Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 156
“JUN was of particular interest, because others and we have recently shown that c-Jun/AP-1 is involved in melanoma phenotype switching (15, 17, 21, 35).”
BackgroundSelf-citationCancer drug addiction is relayed by an ERK2-dependent phenotype switch
Kong, X., Kuilman, T., Shahrabi, A., Boshuizen, J., Kemper, K., Song, J.-Y., Niessen, H. W. M., Rozeman, E. A., Geukes Foppen, M. H., Blank, C. U., et al. (2017) · Nature · doi:10.1038/nature24037 · Cited by 153
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., Mangino, G., et al. (2020) · Cancers · doi:10.3390/cancers12102801 · Cited by 145
“Transcription Factors MicroRNA STAT3 [28,122,131,139] miR-7 [59] FLI1 [121] miR-92a-15p [150,152] RUNX [123,129] miR-204-5p [147,149] YAP [14,22,45] miR-211-5p [147] c-MYC [138] miR-126-3p [146] Aryl hyodrocarbon receptor [125] miR-514a [154] SOX proteins (SOX2, SOX10) [58,126,130,131] miR-579-3p [148] β-catenin [120,…”
Two-Faced: Roles of JNK Signalling During Tumourigenesis in the Drosophila Model
La Marca, J. E., & Richardson, H. E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00042 · Cited by 139
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 131
Self-citationBai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Shien, K., Papadimitrakopoulou, V. A., Ruder, D., Behrens, C., Shen, L., Kalhor, N., Song, J., Lee, J. J., Wang, J., Tang, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0148 · Cited by 120
“In contrast, downregulation of JUN, previously reported to be an EMT-promoting factor in cancer cells (33), could not protect cells from rhOSM-induced EMTrelated changes.”
BackgroundSu, Y., Ko, M. E., Cheng, H., Zhu, R., Xue, M., Wang, J., Lee, J. W., Frankiw, L., Xu, A., Wong, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15956-9 · Cited by 101
Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies
Wajapeyee, N., & Gupta, R. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1606 · Cited by 112
Wen, J., Zhao, Z., Huang, L., Wang, L., Miao, Y., & Wu, J. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14848 · Cited by 109
Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 94
Leveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., Sondak, V. K., Messina, J. L., Babacan, N. A., Maria–Engler, S. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.023 · Cited by 99
“[6] Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, et al.”
BackgroundThe Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis
Zhang, X., Yang, L., Szeto, P., Abali, G. K., Zhang, Y., Kulkarni, A., Amarasinghe, K. C., Li, J., Vergara, I. A., Molania, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1362-9 · Cited by 117
Self-citationThe low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
Restivo, G., Diener, J., Cheng, P. F., Kiowski, G., Bonalli, M., Biedermann, T., Reichmann, E., Levesque, M. P., Dummer, R., & Sommer, L. (2017) · Nature Communications · doi:10.1038/s41467-017-01573-6 · Cited by 82
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
“The inhibition of this transcriptional master regulator together with BRAFi [33] elicited cell death decreased a population of melanoma cells with a mesenchymal-like phenotype, which represents an early adaptive state adopted by some melanoma cells in response to BRAFi [33–35].”
BackgroundInflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Hölzel, M., & Tüting, T. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.009 · Cited by 84
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
“17 initiates a transcriptional program that is associated with increased melanoma cell survival (29, 43, 45).”
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 72
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
Webster, M. R., Fane, M. E., Alicea, G. M., Basu, S., Kossenkov, A. V., Marino, G. E., Douglass, S. M., Kaur, A., Ecker, B. L., Gnanapradeepan, K., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.009 · Cited by 79
Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer
Caino, M. C., Seo, J. H., Wang, Y., Rivadeneira, D. B., Gabrilovich, D. I., Kim, E. T., Weeraratna, A. T., Languino, L. R., & Altieri, D. C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93172 · Cited by 80
“Although this process may dictate metastatic competence and ultimately influence disease outcome, its mechanistic underpinnings (9) have remained elusive (11), with only a handful of regulators of cell cycle transitions (12), transcriptional (13) and translational (14) programs, and membrane dynamics of cell motility…”
BackgroundMartin, C. A., Cullinane, C. M., Kirby, L., AbuHammad, S., Lelliott, E. J., Waldeck, K., Young, R. J., Brajanovski, N., Cameron, D. P., Walker, R., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31220 · Cited by 74
“We have previously demonstrated that treatment of melanoma cell lines for 3 weeks with PLX4720 leads to this drugtolerant state.(13) To assess if the combination of palbociclib plus PLX4720 overcame the development of PLX4720 induced drug tolerance, we treated cells for 3 weeks with PLX4720 plus palbociclib and then s…”
BackgroundSelf-citationThe Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Redfern, A. D., Spalding, L. J., & Thompson, E. W. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9906-x · Cited by 68
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 75
“Moreover, TGFb activates the AP-1 pathway leading the production of c-Jun and JunB, respectively in epidermal keratinocytes and dermal fibroblasts (163), known to be involved in the process of phenotype switching and BRAF inhibitor resistance in melanoma (Table 2) (49, 51).”
BackgroundInfluentialDisrupting cellular memory to overcome drug resistance
Harmange, G., Hueros, R. A. R., Schaff, D. L., Emert, B., Saint-Antoine, M., Kim, L. C., Niu, Z., Nellore, S., Fane, M. E., Alicea, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41811-8 · Cited by 60
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
Misek, S. A., Appleton, K. M., Dexheimer, T. S., Lisabeth, E. M., Lo, R. S., Larsen, S. D., Gallo, K. A., & Neubig, R. R. (2019) · Oncogene · doi:10.1038/s41388-019-1074-1 · Cited by 73
Roy, J. P., Halford, M. M., & Stacker, S. A. (2018) · Growth Factors · doi:10.1080/08977194.2018.1472089 · Cited by 58
“Numerous recent studies demonstrated the key role of WNT5A in the development and maintenance of resistance to BRAFi in melanoma (Prasad et al., 2015; Ramsdale et al., 2015; Webster et al., 2015a, 2015b).”
BackgroundAP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells
Comandante-Lou, N., Baumann, D. G., & Fallahi‐Sichani, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111147 · Cited by 60
Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance
Lü, Y., Bintz, M., Yang, Y., Robert, L., Ng, A. H. C., Liu, V., Ribas, A., Heath, J. R., & Wei, W. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007034 · Cited by 52
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
“C-Jun itself mediates BRAF inhibitor resistance and promotes invasion and cell survival during drug adaptation [158].”
BackgroundPhenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma
Roesch, A., Paschen, A., Landsberg, J., Helfrich, I., Becker, J. C., & Schadendorf, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.023 · Cited by 53
“In intrinsically MAPK inhibitor-resistant BRAFmutant melanoma cells, JNK pathway activation has been lately identified as regulatory mechanism for the induction of EMT-characteristics [12].”
BackgroundAn actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
Perotti, V., Baldassari, P., Molla, A., Nicolini, G., Bersani, I., Grazia, G., Benigni, F., Maurichi, A., Santinami, M., Anichini, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0729-2 · Cited by 46
Day, E. K., Sosale, N. G., Xiao, A., Zhong, Q., Purow, B. W., & Lazzara, M. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.014 · Cited by 49
“Over the same time course, the transcript abundances of five FRA1 target genes (predicted by the NCBI BioSystems Database) that have been implicated in contributing to kinase inhibitor resistance (Geer et al., 2010; Wykosky et al., 2015; Ramsdale et al., 2015; Kim et al., 2012; Kesanakurti et al., 2012; Saito et al.,…”
Lombardo, J. A., Aliaghaei, M., Nguyen, Q., Kessenbrock, K., & Haun, J. B. (2021) · Nature Communications · doi:10.1038/s41467-021-23238-1 · Cited by 56
Rather, R. A., Bhagat, M., & Singh, S. K. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108321 · Cited by 46
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
“Such a phenotype has been linked to BRAFi resistance in several previous studies, where it was described as a cell-autonomous mechanism of resistance [24, 26, 36].”
Chen, Y., Tang, Q., Xiao, Q., Yang, L., & Hann, S. S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12958 · Cited by 40
Ca2+/Calmodulin-Dependent Protein Kinase II in Vascular Smooth Muscle
Saddouk, F. Z., Ginnan, R. G., & Singer, H. A. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.08.003 · Cited by 41
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 44
SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma
Hsiao, Y., Su, K., Hsu, Y., Chang, G., Chen, J., Chen, H., Hong, Q.-S., Hsu, S.-C., Kang, P.-H., Hsu, C.-Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10088 · Cited by 42
“Furthermore, c-JUN expression was found to parallel with SNAI2 expression, and correlated with a mesenchymal gene signature in a panel of melanoma cell lines and a patient cohort [38].”
BackgroundKunz, M., & Hölzel, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9657-1 · Cited by 42
“In line with these findings, c-Jun also promotes EMT-like transitions in melanoma and the acquisition of a MITF-low/AXLhigh phenotype [136].”
ResultProteomic identification of a marker signature for MAPKi resistance in melanoma
Paulitschke, V., Eichhoff, O. M., Gerner, C., Paulitschke, P., Bileck, A., Mohr, T. T., Cheng, P. F., Leitner, A., Guenova, E., Saulīte, I., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201695874 · Cited by 34
“Based on our data, this IGFBP7-PTRF link seems to be important in BRAFi resistance, which might be regulated by the JUN pathway (Fig 3I). c-Jun was shown to mediate phenotype switching and BRAFi resistance in melanoma by transcriptomics (Ramsdale et al , 2015).”
Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Thakur, R., Laye, J. P., Lauss, M., Diaz, J. M. S., O'Shea, S. J., Poźniak, J., Filia, A., Harland, M., Gascoyne, J., Randerson‐Moor, J. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3659 · Cited by 36
“Ulceration (present), n (%) 228 (33) 16 (23) 32 (26) 30 (41) 53 (37) 38 (28) 59 (42) 0.”
BackgroundMALT1 promotes melanoma progression through JNK/c-Jun signaling
Wang, Y., Zhang, G.-H., Jin, J. Y., Degan, S., Tameze, Y., & Zhang, J. Y. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.68 · Cited by 32
Emmons, M. F., Bennett, R. L., Riva, A., Gupta, K., Carvalho, L. A. D. C., Zhang, C., Macaulay, R. J. B., Dupéré-Richer, D., Fang, B., Seto, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43519-1 · Cited by 39
“These fi ndings are supported by previous work showing that both AP-1/Jun and TEAD ’ s have also are important drivers of BRAFi resistance in melanoma 43,44 .”
Mathematical Modeling of Streptococcus pneumoniae Colonization, Invasive Infection and Treatment
Domínguez‐Hüttinger, E., Boon, N. J., Clarke, T. B., & Tanaka, R. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00115 · Cited by 41
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines
Verduzco, D., Kuenzi, B. M., Kinose, F., Sondak, V. K., Eroglu, Z., Rix, U., & Smalley, K. S. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0196 · Cited by 34
“The JNK signaling pathway is known to be a critical mechanism of adaptation of BRAF-mutant melanoma cells following BRAF inhibitor treatment, where it drives RTK signaling that limits the effects of MEK/ERK inhibition (46).”
BackgroundLin, G., Yu, B., Liang, Z., Li, L., Qu, S., Chen, K.-H., Zhou, L., Lu, Q., Sun, Y., & Zhu, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162700 · Cited by 35
RetractedKavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 36
“Likewise, the transcription factor ID3, which promotes resistance to BRAF inhibitor (50), decreased after drug removal, while LEF1, which associated with greater sensitivity (19, 26, 51), increased.”
BackgroundCohen-Solal, K., Kaufman, H. L., & Lasfar, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12666 · Cited by 30
“The introduction of the BRAF V600E mutation into immortalized melanocytes (hTERT/CDK4(R24C)/p53DD) (Garraway et al., 2005) results in STAT3 activation (as measured by expression of phosphoSTAT3 (Tyr705) and phosphoSTAT3 (Ser727)) and upregulation of PAX3, a direct STAT3 transcriptional target (Hartman & Czyz, 2015).”
BackgroundInfluentialTargeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
Song, C., Wang, L., Xu, Q., Wang, K., Xie, D., Yu, Z. S., Jiang, K., Liao, L., Yates, J. R., Lee, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46244 · Cited by 37
“In fact, during the preparation of this paper, JNK pathway has been reported as a key mediator of drug resistance in melanoma 23 .”
Systems analysis identifies miR-29b regulation of invasiveness in melanoma
Andrews, M. C., Cursons, J., Hurley, D., Anaka, M., Cebon, J. S., Behren, A., & Crampin, E. J. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0554-y · Cited by 29
“Given roles for phenotype switching [4, 74, 75] and pigmentation changes [76] in melanoma progression, we extracted Gene Ontology database terms associated with melanogenesis or pigmentation (‘Pigmentation’), or epithelial-mesenchymal plasticity (‘EMP’).”
BackgroundMethodCRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 36
“Because these three transcription factors have also been associated with therapies resistance in melanoma (Nallet-Staub et al, 2014; Ramsdale et al, 2015; Verfaillie et al, 2015; Hugo et al, 2015b), our results suggest that regulation of BRAFi-resistance genes expression is multiparametric and…”
BackgroundBioinformatic and cell-based tools for pooled CRISPR knockout screening in mosquitos
Viswanatha, R., Mameli, E., Rodiger, J., Merckaert, P., Feitosa-Suntheimer, F., Colpitts, T. M., Mohr, S. E., Hu, Y., & Perrimon, N. (2021) · Nature Communications · doi:10.1038/s41467-021-27129-3 · Cited by 35
Khaket, T. P., Singh, M. P., Khan, I., & Kang, S. C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105156 · Cited by 30
The expression and role of trefoil factors in human tumors
Zhang, Y., Liu, Y., Wang, L., & Song, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.48 · Cited by 27
“AKT stimulates metastasis through Twist, Snail, Slug, Zeb1, and Zeb2 (58,59).”
BackgroundCRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-Resistant Melanoma
Li, Z., Wang, B., Gu, S. S., Jiang, P., Sahu, A. D., Chen, C.-H., Han, T., Shi, S., Wang, X., Traugh, N. C., et al. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.02.002 · Cited by 25
“JUN acts as a key mediator of BRAFi resistance and its upregulation has been observed in clinically treated patient tumors upon BRAF inhibitor [43,44].”
Jun, an Oncological Foe or Friend?
Jafri, Z., Li, Y., Zhang, J., O’Meara, C. H., & Khachigian, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020555 · Cited by 25
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 22
“Development of c-JUN-mediated mesenchymal-like phenotype: Vemurafenib resistance in BRAF V600E melanoma cell lines is associated with a high abundance of c-JUN and characteristics of a mesenchymal-like phenotype [60].”
Fra-2/AP-1 regulates melanoma cell metastasis by downregulating Fam212b
Chen, G., Li, R., Chen, X., Wang, J., Cao, S., Song, R., Zhao, M.-C., Li, L., Hannemann, N., Schett, G. A., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00660-4 · Cited by 21
Padhye, A., Konen, J. M., Rodriguez, B. L., Fradette, J. J., Ochieng, J. K., Diao, L., Wang, J., Lü, W., Solis, L. S., Batra, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148392 · Cited by 23
Jain, P., Pillai, M., Duddu, A. S., Somarelli, J. A., Goyal, Y., & Jolly, M. K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.007 · Cited by 26
The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma
Wu, M., Hanly, A. M., Gibson, F. T., Fisher, R. J., Rogers, S., Park, K., Zuger, A., Kuang, K., Kalin, J. H., Nocco, S. E., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171063 · Cited by 30
“…negatively regulate MAPK activity, we sought to further explore the functional significance of DUSP1 and DUSP5 as downstream effectors of corin with regard to the MAPK family members ERK, JNK, and p38 MAPK, which have all been implicated in melanoma resistance to targeted therapies (32, 35–37).”
Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines
Noguchi, K., Dalton, A. C., Howley, B. V., McCall, B. J., Yoshida, A., Diehl, J. A., & Howe, P. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177830 · Cited by 23
Kessler, B. E., Mishall, K. M., Kellett, M. D., Clark, E. G., Pugazhenthi, U., Pozdeyev, N. V., Kim, J., Tan, A. C., & Schweppe, R. E. (2018) · Oncogene · doi:10.1038/s41388-018-0617-1 · Cited by 20
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 26
JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells
Du, L., Anderson, A., Nguyen, K. T., Ojeda, S. S., Ortiz-Rivera, I., Nguyen, T., Zhang, T., Kaoud, T. S., Gray, N. S., Dalby, K. N., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00083 · Cited by 19
Poźniak, J., Pedri, D., Landeloos, E., Herck, Y. V., Antoranz, A., Karras, P., Nowosad, A., Makhzami, S., Bervoets, G., Dewaele, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.11.502598 · Cited by 23
Poon, C. L. C., Brumby, A. M., & Richardson, H. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061585 · Cited by 20
Noguchi, K., Dincman, T. A., Dalton, A. C., Howley, B. V., McCall, B. J., Mohanty, B. K., & Howe, P. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003616 · Cited by 17
“8B), but in the presence of exogenous USF-1, vemurafenib activates p38 kinase to activate USF-1 and counterintuitively activate ILEI transcription (15, 20).”
BackgroundPhylogenetic and Expression Analysis of Fos Transcription Factors in Zebrafish
Kubra, K., Gaddu, G. K., Liongue, C., Heidary, S., Ward, A. C., Dhillon, A. S., & Basheer, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710098 · Cited by 20
“Synteny analysis for zebrafish and human FOSL1 and FOSL2 genes was performed using the Genomicus database [57].”
MethodSelf-citationMelanoma protective antitumor immunity activated by catalytic DNA
Cai, H., Cho, E.-A., Li, Y., Sockler, J., Parish, C. R., Chong, B. H., Edwards, J. J., Dodds, T. J., Ferguson, P. M., Wilmott, J. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0306-0 · Cited by 17
Rožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0210-8 · Cited by 17
Scrotal angiokeratoma (Fordyce): histopathological and ultrastructural findings.
Gioglio, L., Porta, C., Moroni, M., Nastasi, G., & Gangarossa, I. (1992) · PubMed · Cited by 18
Pathria, G., Garg, B., Garg, K., Wagner, C., & Wagner, S. N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14713 · Cited by 18
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression
Xue, Z., Qin, L., Xuan, H., Luo, K., Huang, M., Xie, L., Su, Y., Xu, L., Harsh, J., Dale, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado1432 · Cited by 17
“Potential synergistic or antagonistic interaction was evaluated by Bliss independent response surface model ( 61 ).”
FOSL1’s Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review
Khedri, A., Guo, S., Ramar, V., Hudson, B., & Liu, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105362 · Cited by 18
Prasad, G. V. R. K., Dhar, V., & Mukhopadhaya, A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800389 · Cited by 15
“To further confirm the involvement of p38 and JNK in OmpU-mediated proinflammatory responses in macrophages, we used chemical inhibitors VX745 (42) and JNK-IN-XVI (43) that can specifically inhibit p38 and JNK activation, respectively.”
MethodMapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis
Pillai, M., Rajaram, G., Thakur, P., Agarwal, N., Muralidharan, S., Ray, A., Barbhaya, D., Somarelli, J. A., & Jolly, M. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913803 · Cited by 16
“Preclinical data shows that short duration of drug treatment can induce a NCSC phenotype that is highly mesenchymal (14, 16), while prolonged treatment (8-12 weeks) can drive an undifferentiated phenotype.”
BackgroundUpdated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases
Thakur, D., Nandi, A., Gaur, Y. K., Chandrabose, K., Waiker, D. K., Gupta, G. D., & Sharma, K. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05330-y · Cited by 15
“JNK leads to cell proliferation, survival, cell migration [100, 105, 106], apoptosis, senescence, inflammation and stress responses after the activation [6, 69, 107].”
Zhu, E. Y., Riordan, J. D., Vanneste, M., Henry, M. D., Stipp, C. S., & Dupuy, A. J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00310-7 · Cited by 14
Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer
Sun, L., Patai, Á. V., Hogenson, T. L., Fernández-Zapico, M. E., Qin, B., & Sinicrope, F. A. (2021) · Oncogene · doi:10.1038/s41388-021-01910-6 · Cited by 15
“Treatment with JNK-IN-8 has been shown to overcome resistance to a BRAF inhibitor in human melanoma cells [41, 42], and was also able to sensitize pancreatic cancer cells to 5-fluorouracil [43].”
BackgroundParadoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
Webster, M. R., Fane, M. E., Alicea, G. M., Basu, S., Kossenkov, A. V., Marino, G. E., Douglass, S. M., Kaur, A., Ecker, B. L., Gnanapradeepan, K., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.005 · Cited by 18
Su, Y., Liu, C., Lu, X., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S. K., Robert, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724740 · Cited by 12
“…including: down-regulation of SOX10 (Shaffer et al., 2017; Sun et al., 2014) and upregulation of JNK/c-JUN (Fallahi-Sichani et al., 2015, 2017; Ramsdale et al., 2015) in the mesenchymal phenotype, as well as upregulation of KDM5 (Roesch et al., 2010, 2013) in a slow-cycling (likely neural…”
BackgroundInfluentialMartinez, R., Huang, W., Buck, H., Rea, S., Defnet, A. E., Kane, M. A., & Shapiro, P. (2022) · ACS Omega · doi:10.1021/acsomega.1c05361 · Cited by 12
Predicted regulatory SNPs reveal potential drug targets and novel companion diagnostics in psoriasis
Ramírez, A. V. R., Farias, A. F.-S., Álvarez, R. D. C. C., & de, E. P. M. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100096 · Cited by 15
Shin, D. S., Schroeder, M. E., & Anseth, K. S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101592 · Cited by 12
Shapeshifters in cancer: How some tumor cells change phenotype to evade therapy
Keener, A. B. (2016) · Nature Medicine · doi:10.1038/nm1116-1194 · Cited by 10
Navigating Nongenetic Plasticity in Cancer Drug Resistance
Sun, H., Kumari, N., Melzer, M. E., Backman, V., & Goyal, Y. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071924-084617 · Cited by 11
Mapping convergent regulators of melanoma drug resistance by PerturbFate
Xu, Z., Lu, Z., Ugurbil, A., Abdulraouf, A., Liao, A. S.-H., Zhang, J., Zhou, W. Y., & Cao, J. (2026) · Nature · doi:10.1038/s41586-026-10367-0 · Cited by 16
“By contrast, the undifferentiated-1 state was primarily driven by AP-1 family factors (such as JUN, JUND and FOSL2) downstream of MAPK signalling and TEAD TFs (such as TEAD1 and TEAD4) downstream of Hippo/YAP signalling 31,32 (Fig.”
Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma
Barreno, A., & Orgaz, J. L. (2022) · Cells · doi:10.3390/cells11030518 · Cited by 9
“In fact, melanoma cell lines treated for only 24 h [68,69,74,75] or from 48 to 72 h [74,76–78] with BRAFi, MEKi, or ERKi, display spindleshaped and/or flat morphology, regardless of the MAPK oncogenic driver (BRAF or NRAS mutant) [68].”
BackgroundMany Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
Vachtenheim, J., & Ondrušová, Ľ. (2021) · Life · doi:10.3390/life11050424 · Cited by 10
“Increased expression of the c-JUN oncogene, accompanied by the downregulation of SPROUTY4 and switching the phenotype to (EMT) epithelial-mesenchymal transition, was reported to be the reason behind BRAFi resistance in melanoma cells [51].”
BackgroundNeuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma
Satoh, S., Takatori, A., Ogura, A., Kohashi, K., Souzaki, R., Kinoshita, Y., Taguchi, T., Hossain, M. S., Ohira, M., Nakamura, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep32682 · Cited by 8
Metadata
- Authors
- Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., Bollag, G., Long, G. V., Tulchinsky, E., Rizos, H., Pearson, R. B., McArthur, G. A., Dhillon, A. S., & Ferrao, P. T.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Plexxikon (United States) (US)
- The University of Sydney (AU)
- University of Leicester (GB)
- Melanoma Institute Australia (AU)
- Corresponding author
- Ramsdale, Rachel
- Jorissen, Robert N.
- Ferrao, Petranel T.
- ORCID
- Venue
- Science Signaling
- Published
- 2015-08-18
- Volume
- 8
- Issue
- 390
- Pages
- ra82-ra82
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2318400076
- Cited by
- 143
- References
- 63
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 18 · 2019: 22 · 2018: 15 · 2017: 18 · 2016: 14
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Peter MacCallum Cancer Foundation
- CASS Foundation
- National Health and Medical Research Council of Australia (1042980)
- China Scholarships Council
- Cancer Therapeutics CRC
- Australian National Health and Medical Research Council
- Pfizer Australia
- Victorian Endowment for Science, Knowledge and Innovation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- c-Jun, BRAF inhibitor resistance, BRAF V600-mutant melanoma, epithelial-mesenchymal transition, mesenchymal phenotype, Sprouty4, LEF1, JNK, transcriptional cofactors, drug resistance, BRAF/MEK inhibitors, cell migration, cell death
- MeSH terms
- Animals, Humans, Melanoma, Membrane Proteins, Microscopy, Fluorescence, Nerve Tissue Proteins, Phenotype, Blotting, Western, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, JNK Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, Interleukin Receptor Common gamma Subunit, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.